Drug Watch: Agents in late-stage development for the treatment of epilepsy/seizure disorders (PDF) (May 2010)

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with reductions in 24-hour mean systolic blood pressure.

Gavreto used to treat metastatic RET fusion-positive non-small cell lung cancer and RET fusion-positive thyroid cancer.

This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.

Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and gastroesophageal cancers.

David Joyner has been appointed president and CEO of CVS Health effective immediately.

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.